Ewolucja w leczeniu raka stercza. Część 1

Prostate cancer is the most common cancer in men. Strategies relying on androgen deprivation have long been utilized in it’s treatment. However, the therapy of castration-resistant disease still remains challenging. Therapeutic options have rapidly evolved during the last decade. New molecules with unprecedented activity, provided significant survival benefit in advanced disease. This review presents the key aspects of prostate cancer systemic therapy evolution over the last decades. The first part focuses on therapies active in castration-resistant disease. Part two reviews data on earlier therapy lines and principles relevant to devising optimal treatment sequence.